Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipelin | Roche is paying $1.65 ...
Roche Holding AG hired a senior executive from rival Novo Nordisk A/S as the Swiss drugmaker prepares to enter the ...
Novo Nordisk announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche announced a ...
NVO’s stock declined as competition is heating up in the obesity space. With Roche’s latest deal, a new contender enters the obesity space, which could threaten it and Eli Lilly’s dominance ...
Basel: Roche has announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results